Silence Therapeutics Plc (SLN) Stock Price & Analysis
Silence Therapeutics Plc (SLN) fell 3.53% to USD 6.01 as of June 10, 2026 at 05:53 UTC, according to Nexqual real-time market data.
SLN last closed at USD 6.23; the session ranged USD 5.9–6.56 on volume of 183,386 shares. Market capitalization is $283.88M, with a 52-week range of USD 4.19–8.4 (NGM). Source: Nexqual, June 10, 2026 at 05:53 UTC.
Key Statistics (as of June 10, 2026 at 05:53 UTC)
| Price | USD 6.01 |
|---|---|
| Change | ▼ 3.53% (down) |
| Previous Close | USD 6.23 |
| Open | USD 6.29 |
| Day Range | USD 5.9 – 6.56 |
| 52-Week Range | USD 4.19 – 8.4 |
| Volume | 183,386 shares |
| Market Cap | $283.88M |
| Exchange | NGM |
Technical Analysis (SLN)
Nexqual's technical model rates SLN "STRONG SELL" based on 0 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 05:53 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 42.03 (neutral) |
| vs SMA50 | Below (USD 6.65) |
| MACD | -0.11 (negative) |
Analyst Ratings (SLN)
Wall Street analysts rate SLN "Buy" based on 5 analysts, with a mean price target of USD 31.2 (range USD 4–75), per Nexqual as of June 10, 2026 at 05:53 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 31.2 |
| High Target | USD 75 |
| Low Target | USD 4 |
| Buy / Hold / Sell | 5 / 0 / 1 |
Earnings (SLN)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.11 |
| Revenue Estimate | $1.04M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.33 vs est -0.09 ▼ miss |
| 2025-12-31 | USD -0.27 vs est -0.49 ▲ beat |
| 2025-09-30 | USD -0.15 vs est -0.21 ▲ beat |
| 2025-06-30 | USD -0.55 vs est -0.21 ▼ miss |
Source: Nexqual, June 10, 2026 at 05:53 UTC.
Financials & Fundamentals (SLN)
| Total Revenue | $839,000 |
|---|---|
| Revenue Growth (YoY) | +197.20% |
| Gross Margin | +79.50% |
| Operating Margin | -3565.40% |
| Profit Margin | +0.00% |
| ROE | -92.56% |
| Debt / Equity | 0.28 |
| Current Ratio | 9.83 |
| Total Cash | $70.08M |
| Total Debt | $136,000 |
| Free Cash Flow | $-44.56M |
Source: Nexqual, June 10, 2026 at 05:53 UTC.
Financial Health Score (SLN)
Nexqual rates Silence Therapeutics Plc's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 05:53 UTC.
| Growth | Critical — Revenue -99% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $70M cash, no debt |
| Cash Flow | Weak — FCF negative: -$45M, burning cash |
| Efficiency | Critical — ROE -93%, ROA -29.8% |
Ownership (SLN)
| Insider Ownership | +24.38% |
|---|---|
| Institutional Ownership | +44.41% |
| Shares Outstanding | 47.23M |
| Float | 24.92M |
| Short % of Float | +5.76% |
Source: Nexqual, June 10, 2026 at 05:53 UTC.
Leadership (SLN)
Silence Therapeutics Plc is led by Iain Gladstone Ross B.Sc., BSc (Hons), C.DIR, CH.D (age 71), Interim CEO & Chairman of the Board, per Nexqual as of June 10, 2026 at 05:53 UTC.
| Interim CEO & Chairman of the Board | Iain Gladstone Ross B.Sc., BSc (Hons), C.DIR, CH.D (age 71) |
|---|---|
| Executive VP, CFO, Secretary & Executive Director | Rhonda L. Hellums (age 54) |
| Chief Scientific Officer | Marie Wikstrom Lindholm |
Major Backers & Investors (SLN)
Notable institutional backers of Silence Therapeutics Plc include TCG Crossover Management, LLC, Siren, L.L.C., Redmile Group, LLC, according to Nexqual as of June 10, 2026 at 05:53 UTC.
Active Investors
| Investor | Stake |
|---|---|
| TCG Crossover Management, LLC | 6.42% |
| Siren, L.L.C. | 6.16% |
| Redmile Group, LLC | 4.58% |
| Nantahala Capital Management, LLC | 4.54% |
| Citadel | 2.61% |
| Millennium Management | 2.27% |
| Great Point Partners LLC | 2.16% |
| Nextech Invest, Ltd. | 2.02% |
Source: Nexqual, June 10, 2026 at 05:53 UTC.
From Silence Therapeutics Plc's Latest SEC 10-K Filing (filed 2026-03-05)
Key Strengths & Strategy (as disclosed to the SEC)
- Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases.
- The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases.
- It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PHVS | Pharvaris N.V. | USD 31.6 | ▲ 1.64% |
| BCYC | Bicycle Therapeutics plc | USD 4.17 | ▼ 0.71% |
| KROS | Keros Therapeutics, Inc. | USD 10.07 | ▼ 2.23% |
| IVA | Inventiva S.A. - American Depos | USD 3.97 | ▼ 1.49% |
| TRDA | Entrada Therapeutics, Inc. | USD 6.37 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 05:53 UTC. This page is informational and not investment advice.